Deliverables

Work package 1: Programme management and coordination

Deliverable 1.5 Legal and Ethics Policy Paper, September 2018

Grant agreement, November 2016

Deliverable 1.2 Establishment of Governing Board, February 2017

Deliverable 1.8 Establishment of Stakeholder Forum and Advisory Board

Work package 2: Knowledge hub

Deliverable 2.3 2018 Strategy for the communication and dissemination of HBM4EU results

Deliverable 2.4 2018 Programme of training activities, materials and capacity building mechanisms

Deliverable 2.7 Online library: content and use, November 2018

Deliverable 2.5 2019 Strategy for the communication and dissemination of HBM4EU results, October 2018

Deliverable 2.1 HBM4EU Website, March 2017

Deliverable 2.2 Strategy for the communication and dissemination of HBM4EU results, March 2017

Work package 4: Prioritisation and input to the annual work plan

Deliverable Report 4.4 - First report on the stakeholder consultation and the mapping of needs

Deliverable 4.5 Second list of HBM4EU priority substances and Chemical Substance Group Leaders for 2019-2021

Deliverable 4.6 Scoping documents for the second round priority substances

Deliverable 4.1 Template for the submission of rapid requests, May 2017

Deliverable 4.2 Scoping documents on HBM4EU priority substances for 2018, June 2017

Deliverable 4.3 Prioritisation strategy and criteria

Work package 5: Translation of results into policy

Deliverable 5.4 A (phased) plan for action: from Human Biomonitoring to targeted policy action - Report of Case Study 1 – phthalates and bisphenols

Deliverable 5.1 Human biomonitoring in risk assessment: analysis of the current practice and 1st examples on the use of HBM in risk assessments of HBM4EU priority chemicals

Additional Deliverable 5.1 A (phased) plan for action: how structured multi-actor dialogues on human biomonitoring results can facilitate targeted policy action (generic canvas for HBM4EU)

Deliverable 5.2 1st substance-group specific derivation of EU-wide health-based guidance values

Deliverable 5.3 Scoping paper on the development of an indicator on chemical exposure in the European population

Work package 6: Sustainability and capacity building

Deliverable 6.1 First set of key indicators for HBM4EU, June 2017

Additional deliverable 6.1 Preliminary Report on different options for a sustainable EU HBM and feedback from different institutions

Deliverable 6.3 Consultation on a sustainable HBM initiative in Europe

Work package 7: Survey design and fieldwork preparation

Deliverable 7.6 - 2nd prioritisation Report on survey design: Study protocols, SOPs and Guidelines, tailored and transferred questionnaires for recruitment and sampling

Deliverable 7.4 1st material for communication to participants, including informed consent

Deliverable 7.5 Report on ongoing activities and existing data and data gaps for the 2nd prioritised substances

Additional deliverable 7.2 Literature research and concept for a sample quality study on impact of thawing and freezing on integrity of human samples for selected 1st and 2nd priority substances

Deliverable 7.7 - 2nd set of materials for communication to participants, including informed consent

Deliverable 7.1 Report on ongoing activities and existing data and data gaps for the 1st prioritised substances including a list of metadata that can be uploaded in IPCheM

Deliverable 7.2 Strategy and SOPs for human sample exchange, including ethical demands

Deliverable 7.3 1st prioritisation Report on survey design: Study protocols, SOPs and Guidelines, tailored and transferred questionnaires for recruitment and sampling

Work package 8: Targeted field work surveys and alignment at EU level

Additional Deliverable - Cr fact sheets ; French, Finnish, German, Italian, Portuguese, Dutch and Polish

Deliverable 8.3 First report on targeted new fieldwork study results

Deliverable 8.4 Initial report on strategies adopted to align studies across Europe

Deliverable 8.2 First report on biobank activities, August 2018

Deliverable 8.5 Initial Report on Occupational Studies

Additional deliverable 8.1 Report on access to occupational data

Additional Deliverable AD 8.2 Research plan for chromates study under HBM4EU

Deliverable 8.1 Description of the national programs A strategy to collect EU wide HBM data

  The Deliverable 8.1 presents the strategy of HBM4EU to collect HBM data EU wide in a harmonised way to get comparable HBM data all over Europe.

Work package 9: Laboratory analysis and quality assurance

Deliverable 9.3 Database of candidate laboratories for the 1st prioritisation round of substances

Deliverable 9.4 The Quality Assurance/Quality Control Scheme in the HBM4EU project

Additional Deliverable 9.1 General guidance for new method development within HBM4EU and role of task 9.3 therein

Deliverable 9.6 - Databases of candidate laboratories for the 2nd prioritisation round of substances

Deliverable 9.5 - Prioritised list of biomarkers, matrices and analytical methods for the 2nd prioritisation round of substances

Additional Deliverable 9.2 - Survey of tentative prices for biomarker analyses

Deliverable 9.1 Criteria for the prioritisation of biomarkers, April 2017

Deliverable 9.2 Prioritised list of biomarkers, matrices and analytical methods for the 1st prioritisation round of substances

Work package 10: Data management and analysis

Deliverable 10.4 1st annual list of exposure distributions and/or European reference values

Deliverable 10.1 Data Management Plan, July 2017

Annex to Deliverable 10.1 Data Policy, July 2017

Deliverable 10.2 Statistical Analysis Plan

Work package 11: Linking HBM, health surveys and registers

Deliverable 11.2 - Report on workshop about opportunities and obstacles for linking HBM and health studies

Deliverable 11.3 - Report on opportunities and obstacles of combining HBM and health studies, availability of health studies with biological samples, availability of administrative registers, and guidelines for combining HBM and health studies for the 2nd prioritisation round of substances

Additional Deliverable 11.1 How can the results from BRIDGE Health be incorporated to the work of HBM4EU?

Additional Deliverable 11.2 Criteria for feasibility studies

Deliverable 11.1 Report on opportunities and obstacles of combining HBM and health studies, availability of health studies with biological samples, availability of administrative registers, and guidelines for combining HBM and health studies

  Task 11.1 aims to evaluate the opportunities and obstacles of combining ongoing and/or planned health studies (health examination surveys (HES), cohort studies, dietary surveys, occupational studies, etc.) and HBM.

Work package 12: From HBM to exposure

Deliverable 12.1 Review paper on PBTK/D models for the 1st set of priority compounds

Deliverable 12.3 Biological half-life and internal dosimetry of the 1st set of priority compounds

Additional deliverable 12.4 - Conceptual design of the integrated computational platform

Additional Deliverable AD12.6 “Optimised algorithms for reverse dosimetry“

Additional Deliverable 12.1 Database of exposure-related and ancillary data for priority substances

Deliverable 12.2 Report on the optimal methodology for exposure reconstruction from HBM data

Additional Deliverable 12.2 Roadmap for model PBTK/D model refinement and analysis for priority substances

Work package 13: Establishing exposure health relationships

Deliverable 13.3 - Inventory of available samples and data collected from existing cohorts and preliminary results on exposure- response associations for 1st list of priority substances

WP13&14-joint-activities-LEADERS-and-PARTNERS

The file contains tables with contacts to LEADERS (Table 1) who should coordinate discussions within chemical groups and OTHER PARTNERS (Table 2) who contributes with relevant chemical expertise

Deliverable 13.1 Criteria for the selection of cohort studies, June 2017

Deliverable 13.2 Template for AOP update report for selected priority substances

The objectives of the WP13 within the HBM4EU project include establishment of mechanistic links between the adverse health outcomes in human population and exposures to priority chemical stressors. One of the tools that allow to systematically address this objective are Adverse Outcome Pathways (AOP), a concept formalised within AOPKB.org and AOPWIKI.org, which is being developed by joint efforts of international authorities including OECD, EU and US EPA.

Work Package 14: Effect biomarkers

Deliverable 14.4 Report on results of the selected biomarkers of combined effect [Proof of concept]

Additional Deliverable 14.4 First report on the state of development of new biomarkers of effect

Deliverable 14.3 Report on available biomarkers of effect of utility in human epidemiological studies for the 1st set of prioritised substances

Additional Deliverable 14.3 - WP14 - WP13 Interaction: Delineation of AOPs for the selection of effect biomarkers in the HBM4EU aligned studies Bisphenol A as a case-study

Deliverable 14.1 Criteria for prioritisation of biomarkers of effect

Additional Deliverable 14.2 Granada Workshop: Effect biomarkers & establishing exposure and health relationships

Deliverable 14.2 - List of effect biomarkers for the first set of prioritized substances, September 2018

Work package 15: Mixtures, HBM and human health risks

Deliverable 15.2 - Report Outline and workplan for the joint survey on HBM mixtures: an application to pesticide exposure in hotspots and control areas

Additional Deliverable 15.3 HBM mixture database description and proposal statistical analysis plan

Deliverable 15.3 Report real-life exposure profiles from re-analysis of existing HBM mixture data

Additional Deliverable 15.1 Plan for development of case studies

Work package 16: Emerging chemicals

Additional Deliverable 16.4 Emerging Substances

Deliverable 16.2 Workflow for screening emerging chemicals

Additional Deliverable 16.2 - Emerging chemicals framework

Deliverable 16.1 Prioritised list of known emerging chemicals

Additional Deliverable 16.1 Screening methods inventory

Additional Deliverable 16.3 Direct effect based approaches applied to the screening of emerging substances